Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC

Soohyun Lee, Jae Seon Lee, Jinho Seo, Seon Hyeong Lee, Joon Hee Kang, Jaewhan Song, Soo Youl Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Anticancer drug resistance is a major challenge of cancer therapy. We found that irinotecan-resistant NSCLC cells showed increased mitochondrial oxidative phosphorylation compared to the drug sensitive NSCLC cells. Previously, we found that combined inhibition of aldehyde dehydrogenase using gossypol, and mitochondrial complex I using phenformin, effectively reduced oxidative phosphorylation in NSCLC. Here, we showed that targeting oxidative phosphorylation with gossypol and phenformin abrogated irinotecan resistance in NSCLC. Furthermore, irinotecan treatment by blocking oxidative phosphorylation induced synergistic anti-cancer effect in NSCLC. The pre-clinical xenograft model of human NSCLC also demonstrated a therapeutic response to the dual targeting treatment. Therefore, this combination of gossypol and phenformin increases irinotecan sensitivity as well as preventing irinotecan resistance.

Original languageEnglish
Article number15707
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

irinotecan
Oxidative Phosphorylation
Phenformin
Gossypol
Aldehyde Dehydrogenase
Drug Resistance
Heterografts
Neoplasms

All Science Journal Classification (ASJC) codes

  • General

Cite this

Lee, Soohyun ; Lee, Jae Seon ; Seo, Jinho ; Lee, Seon Hyeong ; Kang, Joon Hee ; Song, Jaewhan ; Kim, Soo Youl. / Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{6ffec4ae9c9841129ef78ff1a5e9a567,
title = "Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC",
abstract = "Anticancer drug resistance is a major challenge of cancer therapy. We found that irinotecan-resistant NSCLC cells showed increased mitochondrial oxidative phosphorylation compared to the drug sensitive NSCLC cells. Previously, we found that combined inhibition of aldehyde dehydrogenase using gossypol, and mitochondrial complex I using phenformin, effectively reduced oxidative phosphorylation in NSCLC. Here, we showed that targeting oxidative phosphorylation with gossypol and phenformin abrogated irinotecan resistance in NSCLC. Furthermore, irinotecan treatment by blocking oxidative phosphorylation induced synergistic anti-cancer effect in NSCLC. The pre-clinical xenograft model of human NSCLC also demonstrated a therapeutic response to the dual targeting treatment. Therefore, this combination of gossypol and phenformin increases irinotecan sensitivity as well as preventing irinotecan resistance.",
author = "Soohyun Lee and Lee, {Jae Seon} and Jinho Seo and Lee, {Seon Hyeong} and Kang, {Joon Hee} and Jaewhan Song and Kim, {Soo Youl}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-33667-6",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC. / Lee, Soohyun; Lee, Jae Seon; Seo, Jinho; Lee, Seon Hyeong; Kang, Joon Hee; Song, Jaewhan; Kim, Soo Youl.

In: Scientific reports, Vol. 8, No. 1, 15707, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC

AU - Lee, Soohyun

AU - Lee, Jae Seon

AU - Seo, Jinho

AU - Lee, Seon Hyeong

AU - Kang, Joon Hee

AU - Song, Jaewhan

AU - Kim, Soo Youl

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Anticancer drug resistance is a major challenge of cancer therapy. We found that irinotecan-resistant NSCLC cells showed increased mitochondrial oxidative phosphorylation compared to the drug sensitive NSCLC cells. Previously, we found that combined inhibition of aldehyde dehydrogenase using gossypol, and mitochondrial complex I using phenformin, effectively reduced oxidative phosphorylation in NSCLC. Here, we showed that targeting oxidative phosphorylation with gossypol and phenformin abrogated irinotecan resistance in NSCLC. Furthermore, irinotecan treatment by blocking oxidative phosphorylation induced synergistic anti-cancer effect in NSCLC. The pre-clinical xenograft model of human NSCLC also demonstrated a therapeutic response to the dual targeting treatment. Therefore, this combination of gossypol and phenformin increases irinotecan sensitivity as well as preventing irinotecan resistance.

AB - Anticancer drug resistance is a major challenge of cancer therapy. We found that irinotecan-resistant NSCLC cells showed increased mitochondrial oxidative phosphorylation compared to the drug sensitive NSCLC cells. Previously, we found that combined inhibition of aldehyde dehydrogenase using gossypol, and mitochondrial complex I using phenformin, effectively reduced oxidative phosphorylation in NSCLC. Here, we showed that targeting oxidative phosphorylation with gossypol and phenformin abrogated irinotecan resistance in NSCLC. Furthermore, irinotecan treatment by blocking oxidative phosphorylation induced synergistic anti-cancer effect in NSCLC. The pre-clinical xenograft model of human NSCLC also demonstrated a therapeutic response to the dual targeting treatment. Therefore, this combination of gossypol and phenformin increases irinotecan sensitivity as well as preventing irinotecan resistance.

UR - http://www.scopus.com/inward/record.url?scp=85055458968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055458968&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-33667-6

DO - 10.1038/s41598-018-33667-6

M3 - Article

C2 - 30356107

AN - SCOPUS:85055458968

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 15707

ER -